Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A hypotrichosis that has material basis in a mutation on chromosome 1p21.1-q21.3.
Features include: Abnormality of the dentition, Absent axillary hair, Abnormal nail morphology, and Hearing abnormality and 5 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 2 | Abnormal nail morphology, Alopecia |
Ears |
EPS8L3 encodes EPS8 signaling adaptor L3 (593 aa). Highest expression in Small Intestine Terminal Ileum (113.5 TPM) and Colon Transverse (97.6 TPM).
Hypotrichosis 5 is associated with mutations in the EPS8L3 gene on chromosome 1.
EPS8L3 is classified as a druggable target (Kinase category) with score 0.0.
Genetic testing for EPS8L3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypotrichosis 5 has been reported in the published literature.
No clinical trials have been registered for hypotrichosis 5.
218 publications have been identified in PubMed for hypotrichosis 5. Kisho has analyzed 113 by research type. Research spans Review / Meta-Analysis (42%), Clinical Trial Publication (25%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 47 | 42% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:11 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1
Hearing abnormality |
Clinical study results
28 |
25% |
Disease patterns and progression | 21 | 19% |
Laboratory research | 6 | 5% |
Patient case studies | 5 | 4% |
New treatment approaches | 4 | 4% |
Other research | 1 | 1% |
Testing and diagnosis research | 1 | 1% |
Huang J (2026). [PMID: 41371419](https://pubmed.ncbi.nlm.nih.gov/41371419/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Wang Z (2026). [PMID: 41501168](https://pubmed.ncbi.nlm.nih.gov/41501168/). *Nat Rev Urol*. [Review / Meta-Analysis]
Esener Z (2026). [PMID: 40701644](https://pubmed.ncbi.nlm.nih.gov/40701644/). *Clin Genet*. [Case Report / Case Series]
Portela Carvalho C (2026). [PMID: 41525162](https://pubmed.ncbi.nlm.nih.gov/41525162/). *Acta Med Port*. [Review / Meta-Analysis]
Bourne A (2026). [PMID: 41779757](https://pubmed.ncbi.nlm.nih.gov/41779757/). *J Drugs Dermatol*. [Review / Meta-Analysis]
Gupta AK (2026). [PMID: 40662444](https://pubmed.ncbi.nlm.nih.gov/40662444/). *Int J Dermatol*. [Clinical Trial Publication]
Hu BD (2026). [PMID: 41740930](https://pubmed.ncbi.nlm.nih.gov/41740930/). *J Allergy Clin Immunol*. [Basic Science / Preclinical]
Starace M (2026). [PMID: 41855013](https://pubmed.ncbi.nlm.nih.gov/41855013/). *Am J Clin Dermatol*. [Epidemiology / Natural History]
Ong MM (2026). [PMID: 41118052](https://pubmed.ncbi.nlm.nih.gov/41118052/). *Am J Clin Dermatol*. [Review / Meta-Analysis]
Moore L (2026). [PMID: 41965049](https://pubmed.ncbi.nlm.nih.gov/41965049/). *Rev Med Virol*. [Review / Meta-Analysis]